Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis.

Gatto M, Wiedemann A, Nomovi N, Reiter K, Schrezenmeier E, Rose T, Szelinski F, Lino AC, Valentino S, Ghirardello A, Dörner T, Doria A.

Front Immunol. 2019 Jan 25;10:29. doi: 10.3389/fimmu.2019.00029. eCollection 2019.


A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.

Duerr M, Schrezenmeier EV, Lehner LJ, Bergfeld L, Glander P, Marticorena Garcia SR, Althoff CE, Sack I, Brakemeier S, Eckardt KU, Budde K, Halleck F.

BMC Nephrol. 2019 Feb 4;20(1):36. doi: 10.1186/s12882-019-1218-0.


Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations.

Schrezenmeier E, Weißenberg SY, Stefanski AL, Szelinski F, Wiedemann A, Lino AC, Dörner T.

Curr Opin Rheumatol. 2019 Mar;31(2):175-184. doi: 10.1097/BOR.0000000000000576.


Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.

Schrezenmeier E, Hoffmann F, Jaeger C, Schrezenmeier J, Lisec J, Glander P, Algharably E, Kreutz R, Budde K, Duerr M, Halleck F.

Ther Drug Monit. 2019 Feb;41(1):53-58. doi: 10.1097/FTD.0000000000000567.


Assessment of the Kidney Donor Profile Index in a European cohort.

Lehner LJ, Kleinsteuber A, Halleck F, Khadzhynov D, Schrezenmeier E, Duerr M, Eckardt KU, Budde K, Staeck O.

Nephrol Dial Transplant. 2018 Aug 1;33(8):1465-1472. doi: 10.1093/ndt/gfy030.


Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives.

Schrezenmeier E, Jayne D, Dörner T.

J Am Soc Nephrol. 2018 Mar;29(3):741-758. doi: 10.1681/ASN.2017040367. Epub 2018 Jan 11.


Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.

Halleck F, Khadzhynov D, Schrezenmeier E, Lehner L, Budde K, Staeck O.

Transplant Proc. 2017 Dec;49(10):2280-2284. doi: 10.1016/j.transproceed.2017.10.004.


Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany.

Schrezenmeier E, Budde K, Staeck O, Lehner L, Duerr M, Khadzhynov D, Dörner T, Halleck F.

Transplant Proc. 2017 Dec;49(10):2269-2273. doi: 10.1016/j.transproceed.2017.09.042.


Immunologic Long-term Outcomes of Living-Related Kidney Transplantations Depending on the Donor-Recipient Relationship.

Khadzhynov D, Halleck F, Lehner L, Schmidt D, Schrezenmeier E, Budde K, Staeck O.

Transplant Proc. 2017 Dec;49(10):2265-2268. doi: 10.1016/j.transproceed.2017.11.005.


[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].

Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, Schmidt E, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erler A, Behrens F, Burmester GR, Dörner T.

Z Rheumatol. 2018 Feb;77(1):28-39. doi: 10.1007/s00393-017-0330-4. German.


Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus-Associated Membranoproliferative Glomerulonephritis.

Schrezenmeier E, Wu K, Halleck F, Liefeldt L, Brakemeier S, Bachmann F, Kron S, Budde K, Duerr M.

Am J Transplant. 2017 Mar;17(3):819-823. doi: 10.1111/ajt.14091. Epub 2016 Nov 22.


Biomarkers in acute kidney injury - pathophysiological basis and clinical performance.

Schrezenmeier EV, Barasch J, Budde K, Westhoff T, Schmidt-Ott KM.

Acta Physiol (Oxf). 2017 Mar;219(3):554-572. doi: 10.1111/apha.12764. Epub 2016 Aug 25. Review.


Urinary NGAL-Positive Acute Kidney Injury and Poor Long-term Outcomes in Hospitalized Patients.

Singer E, Schrezenmeier EV, Elger A, Seelow ER, Krannich A, Luft FC, Schmidt-Ott KM.

Kidney Int Rep. 2016 Jul 25;1(3):114-124. doi: 10.1016/j.ekir.2016.07.003. eCollection 2016 Sep.


Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching?

Halleck F, Khadzhynov D, Liefeldt L, Schrezenmeier E, Lehner L, Duerr M, Schmidt D, Bamoulid J, Lachmann N, Waiser J, Budde K, Staeck O.

Nephrol Dial Transplant. 2016 Dec;31(12):2143-2149. Epub 2016 Jul 1.


No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.

Rissling O, Glander P, Hambach P, Mai M, Brakemeier S, Klonower D, Halleck F, Singer E, Schrezenmeier EV, Dürr M, Neumayer HH, Budde K.

Br J Clin Pharmacol. 2015 Nov;80(5):1086-96. doi: 10.1111/bcp.12664. Epub 2015 Jul 14.


The (pro)renin receptor mediates constitutive PLZF-independent pro-proliferative effects which are inhibited by bafilomycin but not genistein.

Kirsch S, Schrezenmeier E, Klare S, Zaade D, Seidel K, Schmitz J, Bernhard S, Lauer D, Slack M, Goldin-Lang P, Unger T, Zollmann FS, Funke-Kaiser H.

Int J Mol Med. 2014 Apr;33(4):795-808. doi: 10.3892/ijmm.2014.1624. Epub 2014 Jan 14.


Moderate correlations of in vitro versus in vivo pharmacokinetics questioning the need of early microsomal stability testing.

Schrezenmeier E, Zollmann FS, Seidel K, Böhm C, Schmerbach K, Kroh M, Kirsch S, Klare S, Bernhard S, Kappert K, Goldin-Lang P, Skuballa W, Unger T, Funke-Kaiser H.

Pharmacology. 2012;90(5-6):307-15. doi: 10.1159/000343241. Epub 2012 Oct 4.


The (pro)renin receptor ((P)RR) can act as a repressor of Wnt signalling.

Bernhard SM, Seidel K, Schmitz J, Klare S, Kirsch S, Schrezenmeier E, Zaade D, Meyborg H, Goldin-Lang P, Stawowy P, Zollmann FS, Unger T, Funke-Kaiser H.

Biochem Pharmacol. 2012 Dec 15;84(12):1643-50. doi: 10.1016/j.bcp.2012.09.020. Epub 2012 Sep 26.


Supplemental Content

Loading ...
Support Center